Huan Li, Da Li, Liang Wang, Li-Wei Zhang, Jun-Ting Zhang, Xiu-Jian Ma* and Zhen Wu*
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, ChinaFulltext PDF
Objectives: This study aims to report the clinical characteristics and outcomes for the patients with Central Nervous System (CNS) solid Plasma Cell Tumor (PCT), including Solitary Plasmacytoma (SPC) and Multiple Myeloma (MM) with a solid mass. Methods and Materials: Patients’ medical records, surgical reports, and follow-up materials were respectively reviewed. Statistical analysis was used to compare the differences between patients with SPC (n=22) and patients with MM (n=17). Results: The median age was 55.0 years with a male proportion of 48.7%. Tumors located in the skull base, non-skull base and spinal were observed in 24 (61.5%) cases, 8 (20.5%) cases, and 7 (18.0%) cases, respectively. The median diameter was 5.0 cm. Overall, Gross Total Resection (GTR), radiotherapy and chemotherapy were respectively achieved in 13 (33.3%) cases, 15 (44.1%) cases and 16 (47.1%) cases. Follow-up materials were available in 34 (87.2%) patients. When the study ended 21 (61.8%) patients suffered disease progression with a 3-year Progression-Free Survival (PFS) of 38.7%; 11 (32.4%) patients died with a 3-year Overall Survival (OS) of 71.5%. Regarding the differences, SPC affected the skull base more frequently than MM (p=0.006); while patients with MM had a higher frequency (p=0.017) in chemotherapy but the 3-year OS was poorer than SPC. Conclusion: Solid PCT in CNS was a highly heterogeneous disease with a wide spectrum of outcomes. Normalized examinations should be performed prior to the diagnosis of CNS SPC to rule out MM. The treatments for patients with SPC and MM should be differed and further tailored
Li H, Li D, Wang L, Zhang L-W, Zhang J-T, Ma X-J, et al. Plasma Cell Tumor in Central Nervous System: A Report of 39 Cases from a Single Center. Clin Surg. 2022; 7: 3460.